ArticleJournal of feline medicine and surgery2026
Treatment of non-effusive feline infectious peritonitis using oral remdesivir or GS-441524: a randomized, double-blind, non-inferiority trial.
Article in Journal of feline medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesFeline infectious peritonitis (FIP) is a fatal disease caused by feline coronavirus. The nucleoside analog GS-441524, the parent nucleoside of remdesivir, is the most commonly used FIP antiviral. Remdesivir is Food and Drug Administration approved to treat COVID-19 in humans and has been used primarily as an adjunctive treatment for FIP. Data on its efficacy as a first-line oral therapy, as well as its use to treat non-effusive FIP, remain limited. Therefore, this study compares the effectiveness of oral remdesivir vs GS-441524 as a first-line antiviral therapy for cats with non-effusive FIP in a prospective, randomized, double-blind, non-inferiority clinical trial. Furthermore, this study aims to bolster the literature supporting remdesivir use in these cats, anticipating potential future fluctuations in drug cost, availability and legal access.MethodsCats with non-effusive FIP were randomly assigned to receive either oral remdesivir (38-42 mg/kg, n = 10) or oral GS-441524 (18-22 mg/kg, n = 10) q24h for 84 days (12 weeks). Follow-up was conducted at 6 and 16 weeks, and response to therapy, survival and disease-free remission were assessed. Long-term follow-up was also obtained by contacting owners 1.5-2 years after conclusion of the study.ResultsAt week 16, 9/10 (90%) cats treated with remdesivir and 7/10 (70%) cats treated with GS-441524 were alive and in clinical remission. Remdesivir met the statistical criteria for non-inferiority, with a difference in disease-free survival of 20% (90% confidence interval -8.5 to +48.5). All deaths during treatment occurred within the first 11 days of the trial. Long-term follow-up revealed new onset of clinical signs and raised concerns for potential late relapse of disease in four cats (two in each group).Conclusions and relevanceThis study supports the hypothesis that oral remdesivir is non-inferior to GS-441524 for achieving survival and disease-free remission from FIP at 16 weeks. Given evolving global drug access and costs, remdesivir is a viable first-line option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.